Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma
Language English Country Greece Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
26408740
PII: 35/10/5661
Knihovny.cz E-resources
- Keywords
- Metastatic renal carcinoma, biomarkers, immunohistochemistry, prediction, targeted-therapy,
- MeSH
- Tissue Array Analysis methods MeSH
- Adult MeSH
- Immunoenzyme Techniques MeSH
- Indoles therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy mortality secondary MeSH
- Kidney metabolism pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- Survival Rate MeSH
- Biomarkers, Tumor metabolism MeSH
- Kidney Neoplasms drug therapy mortality pathology MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyrroles therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Case-Control Studies MeSH
- Neoplasm Grading MeSH
- Sunitinib MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Indoles MeSH
- Biomarkers, Tumor MeSH
- Antineoplastic Agents MeSH
- Pyrroles MeSH
- Sunitinib MeSH
AIM: To identify tissue biomarkers that are predictive of the therapeutic effect of sunitinib in treatment of metastatic clear cell renal cell carcinoma (mCRCC). MATERIALS AND METHODS: Our study included 39 patients with mCRCC treated with sunitinib. Patients were stratified into two groups based on their response to sunitinib treatment: non-responders (progression), and responders (stable disease, regression). The effect of treatment was measured by comparing imaging studies before the initiation treatment with those performed at between 3rd and 7th months of treatment, depending on the patient. Histological samples of tumor tissue and healthy renal parenchyma, acquired during surgery of the primary tumor, were examined with immunohistochemistry to detect tissue targets involved in the signaling pathways of tumor growth and neoangiogenesis. We selected mammalian target of rapamycine, p53, vascular endothelial growth factor, hypoxia-inducible factor 1 and 2 and carbonic anhydrase IX. We compared the average levels of biomarker expression in both, tumor tissue, as well as in healthy renal parenchyma. Results were evaluated using the Student's t-test. RESULTS: For responders, statistically significant differences in marker expression in tumor tissue versus healthy parenchyma were found for mTOR (4%/16.7%; p=0.01031), p53 (4%/12.7%; p=0.042019), VEGF (62.7%/45%; p=0.019836) and CAIX (45%/15.33%; p=0.001624). A further significant difference was found in the frequency of high expression (more than 60%) between tumor tissue and healthy parenchyma in VEGF (65%/35%; p=0.026487) and CAIX (42%/8%; p=0.003328). CAIX was expressed at high levels in the tumor tissue in both evaluated groups. CONCLUSION: A significantly higher expression of VEGF in CRCC in comparison to healthy parenchyma can predict a better response to sunitinib.